P1 Progress Towards and Commonalities in Vaccine Development Against HIV, TB, and Malaria

P1.1 Advanced Clinical Development of HIV Vaccines

P1.2 Commonalities across vaccine development efforts

P1.3 Progress towards vaccines against TB

P1.4 Global Pipeline for Malaria Vaccines: Progress and Challenges to accelerate vaccine development

P1.5 Gaps in Malaria Vaccines

P2 Innovating for Equity

P2.1 Intensified Mission Indradhanush: Addressing Equity in Immunization

P2.2 Use of Multiple Measures for Immunization Management in Migratory Population

P2.4 Social Media Initiative in Ukraine: Analysis of Conversations on Polio, Vaccination and Routine Immunization

P2.5 Universal Health Coverage: a people-centred approach

P2.6 Strengthening Vaccination Programs among the Urban Poor: Closing the Equity Gap

P3 Growing Developing Country Vaccine Manufacture

P3.1 Vaccine Production in Developing Countries: an Economic Evaluation

P3.2 Developing Country Vaccine Manufacturers - Access to Immunization

P3.3 Vaccine Manufacturing in Developing Countries: Perspectives on Approaches to Take, and Factors to Consider, towards Sustainable Manufacturing Capacity

P3.4 Addressing Patent Barriers to Vaccine Development & Access

P4 Regulatory Capacity, Challenges, and Convergences

P4.1 Alternative Regulatory Pathways: Opportunities and Challenges

P4.2 Benefits and Challenges: How regulators can reduce time and efforts in the case of public health emergencies?

P4.3 Human Clinical Trial to Support the Development of New Vaccines: Perspective from Thailand

P5 Evidence for Decision Making

P5.1 Development of WHO Full Public Health Value Propositions for vaccines to prevent infectious diseases

P5.2 Evidence for Decision Making

P6 Polio Endgame: Needs and Opportunities

P6.1 Intro Polio Endgame: Needs and Opportunities

P6.2 Global tOPV withdrawal: "The Switch" experience

P6.3 Two years after the tOPV ot bOPV switch: What happened to Poliovirus Type 2?

P6.4 Polio Vaccines - R&D Updates

P6.5 Research for polio policy making: Lessons learned

P7 Discussion with Thought Leaders

W1 Emerging Vaccine Strategies & Technologies

W2 R&D Update: Enteric Vaccines

W3 Pneumococcal Vaccines: Lessons Learned and the Road Ahead

W4 Immunological Principles of Vaccines and Vaccination

W4 Immunological Principles of Vaccines and Vaccination

W5 Epidemic and Pandemic Preparedness

W6 Reaching Adolescents and Pregnant Women

W7 New Vaccine Pipeline: Lessons Learned and Accelerating Progress

W8 Vaccines and Antimicrobial Resistance (AMR)

W9 Antibody-Mediated Prevention

W1.1 MIMIC: an in vitro model of human immunity

W1.1 MIMIC: an in vitro model of human immunity

W1.2 New Vaccine Strategies using cytomegalovirus

W1.3 A novel vaccine technology platform Plasmid Launched Live Attenuated Virus (PLLAV) Vaccines

W2.1 An update on rotavirus vaccines

W2.2 Subunit vaccine technologies for bacterial enteric diseases: Shigella, ETEC and nontyphoidal Salmonella vaccines

W2.3 Controlled Human Infection Models and Enteric Vaccine Development

W3.1 2018 Status of Pneumococcal Conjugate Vaccine Use and Impact

W3.2 Rollout of Pneumococcal Conjugate Vaccine in India

W3.3 The Future of Pneumococcal Conjugate Vaccines

W4.2 Immunological Challenges in vaccination and vaccine development

W4.3 New technologies for studying human immunity

W4.4 RTS,S Malaria Vaccine: Toward an understanding of the immunologic basis of protection

W5.1 WHO R&D Blueprint Update: progress and Plans

W5.2 Influenza Pandemic Risk and Preparedness

W5.3 Epidemic Preparedness: National Security for Thailand

W5.4 Universal Influenza Vaccines and Their Role in Preparedness

W6.1 Reaching Adolescents & Pregnant Women (Introduction)

W6.2 Adolescent Immunization in Developing Countries: Obstacles and Opportunities

W6.3 Maternal and adolescents immunization - a global challenge

W7.1 Global Vaccine Pipeline and Value Proposition

W7.2 Update on RSV Vaccine and mAb development

W7.3 A Hepatitis C Virus Vaccine Update

W7.4 Human Hookworm Vaccine Initiative: a Public Health value proposition leading to societal impact and positive financial returns

W7.5 Target Value Proposition

W8.1 Antimicrobial Resistance and Vaccines

W8.2 Vaccination against bacterial diseases in farmed Atlantic salmon: experience and global applicability

W8.3 The Principle and Process of Autogenous Vaccine

W9.1 Pipeline of HIV monoclonal antibodies for prevention of HIV

W9.2 Monoclonal antibodies for rabies post-exposure prophylaxis

W9.3 Monoclonal Antibodies for Influenza Prevention, Therapy, or Vaccine Antigen Design

W9.4 Antibody Engineering: Optimization of Antibodies for Commercialization